Related Experiment Video
Updated: Apr 5, 2026
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives
João Constantino1, Célia Gomes2, Amílcar Falcão3
1Faculty of Pharmacy and Centre for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.
Abstract:
Dendritic cells (DCs) are versatile elements of the immune system and are best known for their unparalleled ability to initiate and modulate adaptive immune responses. During the past few decades, DCs have been the subject of numerous studies seeking new immunotherapeutic strategies against cancer. Despite the initial enthusiasm, disappointing results from early studies raised some doubts regarding the true clinical value of these approaches. However, our expanding knowledge of DC immunobiology and the definition of the optimal characteristics for antitumor immune responses have allowed a more rational development of DC-based immunotherapies in recent years. Here, after a brief overview of DC immunobiology, we sought to systematize the knowledge provided by 20 years of clinical trials, with a special emphasis on the diversity of approaches used to manipulate DCs and their consequent impact on vaccine effectiveness. We also address how new therapeutic concepts, namely the combination of DC vaccines with other anticancer therapies, are being implemented and are leveraging clinical outcomes. Finally, optimization strategies, new insights, and future perspectives on the field are also highlighted.
Insights
Dendritic cell (DC) immunotherapies show promise for cancer treatment. Recent advancements in understanding DC immunobiology and combining DC vaccines with other therapies are improving clinical outcomes.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Dendritic cells (DCs) are key immune regulators initiating adaptive responses.
- DCs are extensively studied for cancer immunotherapy, but early trials yielded mixed results.
- Advances in DC immunobiology and antitumor response understanding enable rational immunotherapy design.
Purpose of the Study:
- To review 20 years of clinical trials on dendritic cell (DC)-based cancer immunotherapies.
- To analyze diverse DC manipulation strategies and their impact on vaccine effectiveness.
- To explore novel therapeutic combinations and future directions in DC-based cancer treatment.
Main Methods:
- Systematic review of clinical trial data over two decades.
- Analysis of various dendritic cell (DC) manipulation techniques.
- Evaluation of combination therapies involving DC vaccines.
Main Results:
- Diverse approaches to manipulating dendritic cells (DCs) have been employed in clinical trials.
- The effectiveness of DC vaccines is influenced by the manipulation strategies used.
- Combining DC vaccines with other anticancer therapies shows potential for improved clinical outcomes.
Conclusions:
- Dendritic cell (DC) based immunotherapies have evolved significantly.
- Rational development and combination strategies are crucial for enhancing DC vaccine efficacy.
- Future research should focus on optimization and novel therapeutic concepts.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy